The stock of Xbiotech Inc (NASDAQ:XBIT) registered a decrease of 5.26% in short interest. XBIT’s total short interest was 1.65 million shares in February as published by FINRA. Its down 5.26% from 1.74 million shares, reported previously. With 23,200 shares average volume, it will take short sellers 71 days to cover their XBIT’s short positions. The short interest to Xbiotech Inc’s float is 8.38%.
The stock decreased 1.59% or $0.14 during the last trading session, reaching $8.66. About 95,697 shares traded. XBiotech Inc. (NASDAQ:XBIT) has declined 7.38% since February 18, 2018 and is downtrending. It has underperformed by 7.38% the S&P500.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $310.20 million. The company??s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.
More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Nasdaq.com which released: “Dr. Alice Gottlieb to Present Hidradenitis Suppurativa Findings at American Academy of Dermatology Annual Meeting – Nasdaq” on January 28, 2019, also Benzinga.com with their article: “Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut – Benzinga” published on February 07, 2019, Benzinga.com published: “50 Biggest Movers From Yesterday – Benzinga” on February 06, 2019. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Seekingalpha.com and their article: “XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa – Seeking Alpha” published on January 23, 2019 as well as Globenewswire.com‘s news article titled: “Dr. Eric Simpson to Present Bermekimab Results in Atopic Dermatitis at 2019 AAD Annual Meeting – GlobeNewswire” with publication date: January 29, 2019.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.